

**Table 2. Opportunity Cost of Current Practice**

<b>Immunologic Therapy</b>	<b>Doses Administered</b>	<b>Inpatient Medication Cost</b>	<b>Outpatient Medication Cost</b>	<b>Outpatient Reimbursement</b>	<b>Outpatient Medication Margin</b>	<b>Opportunity Cost</b>
Rituximab	72	\$415,926	\$176,462	\$512,065	\$335,603	\$751,530
Adalimumab	12	\$33,052	\$9,240	\$35,467	\$26,227	\$59,279
Infliximab	12	\$35,021	\$17,274	\$38,681	\$21,408	\$56,429
Eculizumab	2	\$35,982	\$25,416	\$30,607	\$5,191	\$41,173
Brentuximab	1	\$9,883	\$6,332	\$14,609	\$8,277	\$18,160
Ofatumumab	4	\$15,524	\$11,774	\$6,204	(\$5,570)	\$9,954
Etanercept	4	\$1,399	\$151	\$2,665	\$2,514	\$3,913
Natalizumab	1	\$4,679	\$1,241	-	(\$1,241)	\$3,438
Denosumab	2	\$3,385	\$2,419	\$1,669	(\$749)	\$2,636
Tocilizumab	1	\$1,441	\$1,038	\$1,340	\$302	\$1,743
<b>Total</b>	111	\$556,292	\$251,345	\$643,308	\$391,962	\$948,254
<b>Annualized Total</b>	<b>270</b>	<b>\$1,353,644</b>	<b>\$611,607</b>	<b>\$1,565,382</b>	<b>\$953,775</b>	<b>\$2,307,419</b>